Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers
- Determine the antitumor activity of Gliadel wafers (carmustine) in the treatment of
recurrent supratentorial low grade glioma.
- Assess the toxicity of this therapy in these patients.
OUTLINE: Patients are stratified by disease (fibrillary astrocytoma vs oligodendroglioma or
Patients receive up to 8 Gliadel wafers (containing carmustine) implanted in the resected
Patients are followed every 2 months.
PROJECTED ACCRUAL: This study will accrue a maximum of 68 patients within 18-24 months.
Primary Purpose: Treatment
Henry S. Friedman, MD
United States: Federal Government
|Duke Comprehensive Cancer Center||Durham, North Carolina 27710|